EP Wealth Advisors LLC Boosts Stake in Zoetis Inc. $ZTS

Key Points

• EP Wealth Advisors LLC has increased its holdings in Zoetis Inc. to approximately $42.66 million, owning about 0.06% of the company after purchasing additional shares during the first quarter.
• Zoetis recently reported quarterly earnings of $1.76 per share, exceeding estimates, with a revenue of $2.46 billion, reflecting a 4.2% year-over-year increase.
• Research analysts have varied opinions on Zoetis; while some have cut price targets from previous highs, the stock maintains a consensus rating of "Moderate Buy" with an average target of $202.43.

EP Wealth Advisors LLC raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 259,118 shares of the company's stock after purchasing an additional 12,018 shares during the period. EP Wealth Advisors LLC owned about 0.06% of Zoetis worth $42,664,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. 1248 Management LLC acquired a new stake in Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis in the first quarter valued at about $29,000. Cornerstone Planning Group LLC grew its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC raised its position in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Down 0.0%

NYSE:ZTS traded down $0.05 during mid-day trading on Friday, reaching $153.15. The company's stock had a trading volume of 1,895,936 shares, compared to its average volume of 2,304,532. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a market cap of $67.87 billion, a P/E ratio of 26.36, a P/E/G ratio of 2.46 and a beta of 0.89. The company's fifty day simple moving average is $153.16 and its two-hundred day simple moving average is $157.72. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the company posted $1.56 EPS. The company's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.